RESUMEN
Diagnosis of pyruvate kinase deficiency (PKD), the most common cause of hereditary non-spherocytic haemolytic anaemia, remains challenging in routine practice and no biomarkers for clinical severity have been characterised. This prospective study enrolled 41 patients with molecularly confirmed PKD from nine North American centres to evaluate the diagnostic sensitivity of pyruvate kinase (PK) enzyme activity and PK:hexokinase (HK) enzyme activity ratio, and evaluate the erythrocyte PK (PK-R) protein level and erythrocyte metabolites as biomarkers for clinical severity. In this population not transfused for ≥90 days before sampling, the diagnostic sensitivity of the PK enzyme assay was 90% [95% confidence interval (CI) 77-97%], whereas the PK:HK ratio sensitivity was 98% (95% CI 87-100%). There was no correlation between PK enzyme activity and clinical severity. Transfusion requirements correlated with normalised erythrocyte ATP levels (r = 0·527, P = 0·0016) and PK-R protein levels (r = -0·527, P = 0·0028). PK-R protein levels were significantly higher in the never transfused [median (range) 40·1 (9·8-73·9)%] versus ever transfused [median (range) 7·7 (0·4-15·1)%] patients (P = 0·0014). The PK:HK ratio had excellent sensitivity for PK diagnosis, superior to PKLR exon sequencing. Given that the number of PKLR variants and genotype combinations limits prognostication based on molecular findings, PK-R protein level may be a useful prognostic biomarker of disease severity and merits further study.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica/sangre , Eritrocitos/enzimología , Hexoquinasa/sangre , Piruvato Quinasa/sangre , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato/sangre , Adolescente , Adulto , Anemia Hemolítica Congénita no Esferocítica/genética , Biomarcadores/sangre , Niño , Preescolar , Femenino , Hexoquinasa/genética , Humanos , Lactante , Masculino , Persona de Mediana Edad , Piruvato Quinasa/genética , Errores Innatos del Metabolismo del Piruvato/genética , Índice de Severidad de la EnfermedadAsunto(s)
Anemia Hemolítica Congénita/diagnóstico , Procesamiento de Imagen Asistido por Computador/métodos , Análisis de la Célula Individual/métodos , Aprendizaje Automático Supervisado , Anemia Hemolítica Congénita/sangre , Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica Congénita no Esferocítica/diagnóstico , Automatización , Viscosidad Sanguínea , Conjuntos de Datos como Asunto , Deformación Eritrocítica , Eritrocitos Anormales/ultraestructura , Humanos , Hidropesía Fetal/sangre , Hidropesía Fetal/diagnóstico , Procesamiento de Imagen Asistido por Computador/instrumentación , Piruvato Quinasa/sangre , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato/sangre , Errores Innatos del Metabolismo del Piruvato/diagnóstico , Reticulocitos/ultraestructura , Análisis de la Célula Individual/instrumentaciónRESUMEN
Anemia is a major health burden worldwide and affects approximately one-third of world's population. It is not a diagnosis; it is a manifestation of an underlying pathophysiology leading to either decreased hemoglobin (Hb), hematocrit (Hct), or red blood cells (RBCs). Iron deficiency anemia is still the most common cause of anemia worldwide. The symptoms are usually due to the underlying compensatory responses to decrease in oxygen delivery to the tissues. Laboratory investigation should start with complete blood count (CBC), reticulocyte count (RC), and peripheral smear evaluation. Further testing depends on these indices, that is, iron parameters and hemoglobinopathies/thalassemia evaluation in microcytic hypochromic anemia, vitamin B12, and folic acid level in macrocytic anemia. Increased RC denotes adequate bone marrow response and points toward hemolytic process and vice versa. Anemia diagnosis can be complex and confusing for the practicing physician. This review tries to give a practical simplistic approach to the diagnosis, focusing mainly on the basic parameters, that is, CBC, RC, and peripheral smear etc. Moreover, we have also tried to provide an update on the pyruvate kinase deficiency, as there has been recent exciting development in the management of these patients.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica , Ácido Fólico/sangre , Hemoglobinas/metabolismo , Hierro/sangre , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato , Vitamina B 12/sangre , Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica Congénita no Esferocítica/diagnóstico , Hematócrito , Humanos , Piruvato Quinasa/sangre , Errores Innatos del Metabolismo del Piruvato/sangre , Errores Innatos del Metabolismo del Piruvato/diagnóstico , Recuento de ReticulocitosRESUMEN
BACKGROUND: Pyruvate kinase (PK) deficiency is the most common cause of nonspherocytic hemolytic anemia owing to defective glycolysis. This study developed and validated an automated method to measure PK activity in red blood cells (RBCs). METHODS: PK catalyzes the reaction of phosphoenolpyruvate with ADP to form pyruvate and ATP. The pyruvate is reduced in the presence of lactate dehydrogenase and NADH to produce lactate and NAD+. The rate of absorbance decrease at 340 nm is proportional to PK activity. PK and hemoglobin (Hb) measurements were performed on a Roche cobas c501 analyzer. After establishing a k-factor, accuracy, linearity, imprecision, sensitivity, and stability were validated and the reference interval was verified. RESULTS: The k-factor was -9477. Accuracy was evaluated by method comparison (n = 56). Linear regression yielded y = 1.0x - 0.57, and R2 of 0.93. Linearity was determined by combining a high sample with hemolyzing solution in 6 different ratios. Linear regression analysis yielded y = 1.02x - 2.68, and R2 of 1.0. The assay was linear to 87 U/dL. Precision was evaluated by testing hemolysates in 3 replicates/day for 10 days. Within-run imprecision was 1.9% and 2.5% and total imprecision was 4.0% and 5.6% at 14.0 and 8.1 U/g Hb, respectively. The limit of blank was 0.0, and the limit of detection was 1.0 U/dL. Stability was determined in 4 sample types at 3 different temperatures; the changes were all <10% when compared with t0. The current PK reference interval of 4.6 to 11.2 U/g Hb was verified. CONCLUSIONS: This automated assay for quantifying PK in RBCs has acceptable performance characteristics and is fit for intended use.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica/diagnóstico , Eritrocitos/enzimología , Hemoglobinas/análisis , Piruvato Quinasa/análisis , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato/sangre , Anemia Hemolítica/etiología , Anemia Hemolítica Congénita no Esferocítica/complicaciones , Automatización de Laboratorios/métodos , Técnicas de Química Analítica , Humanos , Límite de Detección , Piruvato Quinasa/sangre , Errores Innatos del Metabolismo del Piruvato/complicaciones , Reproducibilidad de los ResultadosRESUMEN
BACKGROUND: Pyruvate kinase deficiency is caused by mutations in PKLR and leads to congenital hemolytic anemia. Mitapivat is an oral, small-molecule allosteric activator of pyruvate kinase in red cells. METHODS: In this uncontrolled, phase 2 study, we evaluated the safety and efficacy of mitapivat in 52 adults with pyruvate kinase deficiency who were not receiving red-cell transfusions. The patients were randomly assigned to receive either 50 mg or 300 mg of mitapivat twice daily for a 24-week core period; eligible patients could continue treatment in an ongoing extension phase. RESULTS: Common adverse events, including headache and insomnia, occurred at the time of drug initiation and were transient; 92% of the episodes of headache and 47% of the episodes of insomnia resolved within 7 days. The most common serious adverse events, hemolytic anemia and pharyngitis, each occurred in 2 patients (4%). A total of 26 patients (50%) had an increase of more than 1.0 g per deciliter in the hemoglobin level. Among these patients, the mean maximum increase was 3.4 g per deciliter (range, 1.1 to 5.8), and the median time until the first increase of more than 1.0 g per deciliter was 10 days (range, 7 to 187); 20 patients (77%) had an increase of more than 1.0 g per deciliter in the hemoglobin level at more than 50% of visits during the core study period, with improvement in markers of hemolysis. The response was sustained in all 19 patients remaining in the extension phase, with a median follow-up of 29 months (range, 22 to 35). Hemoglobin responses were observed only in patients who had at least one missense PKLR mutation and were associated with the red-cell pyruvate kinase protein level at baseline. CONCLUSIONS: The administration of mitapivat was associated with a rapid increase in the hemoglobin level in 50% of adults with pyruvate kinase deficiency, with a sustained response during a median follow-up of 29 months during the extension phase. Adverse effects were mainly low-grade and transient. (Funded by Agios Pharmaceuticals; ClinicalTrials.gov number, NCT02476916.).
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica/tratamiento farmacológico , Hemoglobinas/metabolismo , Piperazinas/administración & dosificación , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato/tratamiento farmacológico , Quinolinas/administración & dosificación , Administración Oral , Adolescente , Adulto , Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica Congénita no Esferocítica/genética , Catecoles , Esquema de Medicación , Femenino , Estudios de Seguimiento , Cefalea/inducido químicamente , Humanos , Masculino , Mutación , Piperazinas/efectos adversos , Piruvato Quinasa/sangre , Piruvato Quinasa/genética , Errores Innatos del Metabolismo del Piruvato/sangre , Errores Innatos del Metabolismo del Piruvato/genética , Quinolinas/efectos adversos , Trastornos del Inicio y del Mantenimiento del Sueño/inducido químicamente , Tirfostinos , Adulto JovenRESUMEN
Adenylate kinase (AK) deficiency is a rare erythroenzymopathy associated with hereditary nonspherocytic haemolytic anaemia along with mental/psychomotor retardation in few cases. Diagnosis of AK deficiency depends on the decreased level of enzyme activity in red cell and identification of a mutation in the AK1 gene. Until, only eight mutations causing AK deficiency have been reported in the literature. We are reporting two novel missense mutation (c.71A > G and c.413G > A) detected in the AK1 gene by next-generation sequencing (NGS) in a 6-year-old male child from India. Red cell AK enzyme activity was found to be 30% normal. We have screened a total of 32 family members of the patient and showed reduced red cell enzyme activity and confirm mutations by Sanger's sequencing. On the basis of Sanger sequencing, we suggest that the proband has inherited a mutation in AK1 gene exon 4 c.71A > G (p.Gln24Arg) from paternal family and exon 6 c.413G > A (p.Arg138His) from maternal family. Bioinformatics tools, such as SIFT, Polymorphism Phenotyping v.2, Mutation Taster, MutPred, also confirmed the deleterious effect of both the mutations. Molecular modelling suggests that the structural changes induced by p.Gln24Arg and p.Arg138His are pathogenic variants having a direct impact on the structural arrangement of the region close to the active site of the enzyme. In conclusion, NGS will be the best solution for diagnosis of very rare disorders leading to better management of the disease. This is the first report of the red cell AK deficiency from the Indian population.
Asunto(s)
Adenilato Quinasa/genética , Anemia Hemolítica Congénita no Esferocítica/genética , Eritrocitos/enzimología , Mutación Missense , Adenilato Quinasa/sangre , Adenilato Quinasa/química , Adenilato Quinasa/deficiencia , Adulto , Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica Congénita no Esferocítica/diagnóstico , Anemia Hemolítica Congénita no Esferocítica/enzimología , Niño , Análisis Mutacional de ADN/métodos , Femenino , Predisposición Genética a la Enfermedad , Herencia , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , India , Masculino , Modelos Moleculares , Linaje , Fenotipo , Conformación Proteica , Relación Estructura-ActividadRESUMEN
Pyruvate kinase deficiency (PKD) is the most common glycolytic defect leading to hemolytic anemia. PKD is caused by the mutations in the PKLR gene; however, the detection of a decreased PK activity should be first measured for rapid diagnosis. We report here the case of a 1-year-old girl with mild hemolysis and PKD. At the time of the study, the patient showed a hemoglobin level of 9.5 g/dL, mean corpuscular volume of 93 fL, reticulocyte of 6.7%, and lactate dehydrogenase of 218 IU/L. Peripheral blood smear showed polychromasia, anisocytosis, tear drop cells, fragmented eyrtrocytes, and target cells. When a biochemical analysis was performed in our patient and her parents who had consanguinity, a decreased PK activity was detected in the patient and her father. After the molecular study of PKLR gene, a new homozygote variant, c.1708G>T (pVal570Leu), was found in our patient and her father. Her father had a misdiagnosis of Gilbert syndrome because he had unconjugated hyperbilirubinemia and not anemia. Her mother was also a carrier of the mutation in heterozygous state. Patients presenting with hemolytic anemia, either severe or mild hemolytic anemia, should be screened for PKD in the first year of life. Patients with mild hemolytic findings can be followed-up with misdiagnoses.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica , Errores Diagnósticos , Hemólisis , Homocigoto , Mutación Missense , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato , Sustitución de Aminoácidos , Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica Congénita no Esferocítica/genética , Femenino , Hemoglobinas/metabolismo , Humanos , Lactante , Piruvato Quinasa/sangre , Piruvato Quinasa/genética , Errores Innatos del Metabolismo del Piruvato/sangre , Errores Innatos del Metabolismo del Piruvato/genética , Recuento de ReticulocitosRESUMEN
Pyruvate kinase deficiency (PKD) is the most common enzyme defect of glycolysis and an important cause of hereditary, nonspherocytic hemolytic anemia. The disease has a worldwide geographical distribution but there are no verified data regarding its frequency. Difficulties in the diagnostic workflow and interpretation of PK enzyme assay likely play a role. By the creation of a global PKD International Working Group in 2016, involving 24 experts from 20 Centers of Expertise we studied the current gaps in the diagnosis of PKD in order to establish diagnostic guidelines. By means of a detailed survey and subsequent discussions, multiple aspects of the diagnosis of PKD were evaluated and discussed by members of Expert Centers from Europe, USA, and Asia directly involved in diagnosis. Broad consensus was reached among the Centers on many clinical and technical aspects of the diagnosis of PKD. The results of this study are here presented as recommendations for the diagnosis of PKD and used to prepare a diagnostic algorithm. This information might be helpful for other Centers to deliver timely and appropriate diagnosis and to increase awareness in PKD.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica/diagnóstico , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato/diagnóstico , Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica Congénita no Esferocítica/genética , Anemia Hemolítica Congénita no Esferocítica/fisiopatología , Artefactos , Recuento de Células Sanguíneas , Conservación de la Sangre , Análisis Mutacional de ADN , Eritrocitos/enzimología , Reacciones Falso Negativas , Reacciones Falso Positivas , Humanos , Piruvato Quinasa/sangre , Piruvato Quinasa/genética , Errores Innatos del Metabolismo del Piruvato/sangre , Errores Innatos del Metabolismo del Piruvato/genética , Errores Innatos del Metabolismo del Piruvato/fisiopatología , Valores de Referencia , Reticulocitos , Sensibilidad y Especificidad , Análisis de Secuencia de ADN , Espectrofotometría , Factores de TiempoRESUMEN
The most frequent causes of hemolytic anemias are immune or infectious diseases, drug induced hemolysis, thrombotic microangiopathies, hereditary spherocytosis, glucose-6-phosphate dehydrogenase or pyruvate kinase deficiencies, thalassemia's and sickle cell disease. Sometimes no cause is found because a rarer etiology is involved. The goal of this review is to remember some unfrequent constitutional or acquired causes and to point out difficulties to avoid wrong interpretations of analysis results.
Asunto(s)
Anemia Hemolítica/diagnóstico , Anemia Hemolítica/etiología , Anemia Hemolítica/sangre , Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica Congénita no Esferocítica/complicaciones , Anemia Hemolítica Congénita no Esferocítica/diagnóstico , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/complicaciones , Anemia de Células Falciformes/diagnóstico , Diagnóstico Diferencial , Deficiencia de Glucosafosfato Deshidrogenasa/sangre , Deficiencia de Glucosafosfato Deshidrogenasa/complicaciones , Deficiencia de Glucosafosfato Deshidrogenasa/diagnóstico , Pruebas Hematológicas/métodos , Pruebas Hematológicas/normas , Humanos , Piruvato Quinasa/sangre , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato/sangre , Errores Innatos del Metabolismo del Piruvato/complicaciones , Errores Innatos del Metabolismo del Piruvato/diagnóstico , Esferocitosis Hereditaria/sangre , Esferocitosis Hereditaria/complicaciones , Esferocitosis Hereditaria/diagnóstico , Microangiopatías Trombóticas/sangre , Microangiopatías Trombóticas/complicaciones , Microangiopatías Trombóticas/diagnósticoRESUMEN
INTRODUCTION: Development of additional parameters for complete blood count has emerged in recent hematology analyzers, leading to many publications. However, few studies have been conducted on advanced RBC parameters and hemolytic anemias. We investigated the interest of Sysmex unique parameters, MicroR and HypoHe, as well as the immature fraction of reticulocytes (IRF) in combination with complete blood and reticulocyte count, for screening hereditary spherocytosis (HS) and pyruvate kinase deficiency. METHODS: We analyzed 182 samples using Sysmex XE-5000 analyzers from a cohort of red cell disorder patients from the Rouen University Hospital. These included 47 HS, 17 pyruvate kinase deficiencies, sickle cell diseases and trait, ß-thalassemia minor, iron deficiencies, and 489 samples from a routine group. RESULTS: Combining five parameters (hemoglobin level, reticulocyte count, IRF, MicroR, and %HypoHe), we developed a specific screening tool for HS allowing a sensitivity of 100% and a specificity of 92.1% and a specific screening tool for pyruvate kinase deficiencies allowing a sensitivity of 100% and a specificity of 96.5%. These parameters were also found accurate in infants and in HS without anemia. CONCLUSION: We propose a costless, easy-to-use, and efficient approach to detect HS and pyruvate kinase deficiencies using Sysmex analyzers. These screening tools may help diagnosis of these disorders, help prevent complications, and result in a better management of these patients.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica/sangre , Eritrocitos Anormales/metabolismo , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato/sangre , Reticulocitos/metabolismo , Esferocitosis Hereditaria/sangre , Anemia Hemolítica Congénita no Esferocítica/patología , Recuento de Células Sanguíneas/instrumentación , Recuento de Células Sanguíneas/métodos , Eritrocitos Anormales/patología , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Piruvato Quinasa/sangre , Errores Innatos del Metabolismo del Piruvato/patología , Reticulocitos/patología , Esferocitosis Hereditaria/patologíaRESUMEN
In this study, we performed a genome-wide N-ethyl-N-nitrosourea (ENU) mutagenesis screen in mice to identify novel genes or alleles that regulate erythropoiesis. Here, we describe a recessive mouse strain, called RBC19, harbouring a point mutation within the housekeeping gene, Tpi1, which encodes the glycolysis enzyme, triosephosphate isomerase (TPI). A serine in place of a phenylalanine at amino acid 57 severely diminishes enzyme activity in red blood cells and other tissues, resulting in a macrocytic haemolytic phenotype in homozygous mice, which closely resembles human TPI deficiency. A rescue study was performed using bone marrow transplantation of wild-type donor cells, which restored all haematological parameters and increased red blood cell enzyme function to wild-type levels after 7â weeks. This is the first study performed in a mammalian model of TPI deficiency, demonstrating that the haematological phenotype can be rescued.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica/complicaciones , Anemia Hemolítica Congénita no Esferocítica/genética , Anemia Hemolítica/complicaciones , Anemia Hemolítica/terapia , Trasplante de Médula Ósea , Errores Innatos del Metabolismo de los Carbohidratos/complicaciones , Errores Innatos del Metabolismo de los Carbohidratos/genética , Mutagénesis , Triosa-Fosfato Isomerasa/deficiencia , Anemia Hemolítica/sangre , Anemia Hemolítica Congénita no Esferocítica/sangre , Animales , Errores Innatos del Metabolismo de los Carbohidratos/sangre , Modelos Animales de Enfermedad , Eritrocitos/metabolismo , Etilnitrosourea , Glucólisis , Homocigoto , Ratones , Ratones Mutantes , Mutación Missense/genética , Fenotipo , Triosa-Fosfato Isomerasa/sangre , Triosa-Fosfato Isomerasa/genéticaRESUMEN
Glucose-6-phosphate isomerase (GPI) deficiency, a genetic disorder responsible for chronic nonspherocytic hemolytic anemia, is the second most common red blood cell glycolytic enzymopathy. We report three patients from two unrelated families of Czech and Slovak origin with macrocytic hemolytic anemia due to GPI deficiency. The first patient had 15% of residual GPI activity resulting from two new heterozygous missense mutations c.478T>C and c.1414C>T leading to substitutions p.(Ser160Pro) and p.(Arg472Cys). Two other patients (siblings) inherited the same c.1414C>T p.(Arg472Cys) mutation in a homozygous constitution and lost approximately 89% of their GPI activity. Erythroid hyperplasia with dysplastic features was observed in the bone marrow of all three patients. Low hepcidin/ferritin ratio and elevated soluble transferrin receptor detected in our GPI-deficient patients suggest disturbed balance between erythropoiesis and iron metabolism contributing to iron overload.
Asunto(s)
Sustitución de Aminoácidos , Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica Congénita no Esferocítica/genética , Células Eritroides/metabolismo , Glucosa-6-Fosfato Isomerasa/genética , Hepcidinas/sangre , Mutación , Alelos , Anemia Hemolítica Congénita no Esferocítica/diagnóstico , Biomarcadores , Biopsia , Médula Ósea/patología , Niño , Índices de Eritrocitos , Eritropoyesis/genética , Femenino , Regulación de la Expresión Génica , Genotipo , Glucosa-6-Fosfato Isomerasa/química , Humanos , Hierro/metabolismo , Masculino , Modelos Moleculares , Conformación Proteica , Análisis de Secuencia de ADN , Relación Estructura-ActividadAsunto(s)
Anemia Hemolítica Congénita no Esferocítica/sangre , Puente Cardiopulmonar/métodos , Implantación de Prótesis de Válvulas Cardíacas/métodos , Estenosis de la Válvula Mitral/sangre , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato/sangre , Anemia Hemolítica Congénita no Esferocítica/diagnóstico por imagen , Anemia Hemolítica Congénita no Esferocítica/cirugía , Niño , Humanos , Masculino , Estenosis de la Válvula Mitral/diagnóstico por imagen , Estenosis de la Válvula Mitral/cirugía , Piruvato Quinasa/sangre , Errores Innatos del Metabolismo del Piruvato/diagnóstico por imagen , Errores Innatos del Metabolismo del Piruvato/cirugíaRESUMEN
Unrelated cord blood transplantation (CBT) was performed for the treatment of pyruvate kinase (PK) deficiency in a female pediatric patient at the age of 1 year 7 months, who had been in severe and frequent transfusion-dependent hemolytic anemia, despite red blood cell (RBC) PK activity 5.52 IU/gHb. pyruvate kinase-liver and RBC (PK-LR) had a compound heterozygous mutation located on exon 8: c.1044G > T/c.1076G > A (K348N/R359H). Hemoglobin and RBC PK corrected to 13.5 g/dL and 9.00 IU/gHb, respectively, with gene correction at 6 months after CBT. CBT should be considered as an option for useful treatment in children with severe PK deficiency in the absence of HLA identical sibling with normal RBC PK activity.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica/cirugía , Eritrocitos/citología , Sangre Fetal/citología , Trasplante de Células Madre Hematopoyéticas/métodos , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato/cirugía , Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica Congénita no Esferocítica/diagnóstico , Femenino , Humanos , Lactante , Piruvato Quinasa/sangre , Errores Innatos del Metabolismo del Piruvato/sangre , Errores Innatos del Metabolismo del Piruvato/diagnósticoRESUMEN
Pyruvate kinase (PK) deficiency is an iron-loading anaemia characterized by chronic haemolysis, ineffective erythropoiesis and a requirement for blood transfusion in most cases. We studied 11 patients from 10 unrelated families and found nine different disease-causing PKLR mutations. Two of these mutations - the point mutation c.878A>T (p.Asp293Val) and the frameshift deletion c.1553delG (p.(Arg518Leufs*12)) - have not been previously described in the literature. This frameshift deletion was associated with an unusually severe phenotype involving neonatal hyperferritinaemia that is not typical of PK deficiency. No disease-causing mutations in genes associated with haemochromatosis could be found. Inappropriately low levels of hepcidin with respect to iron loading were detected in all PK-deficient patients with increased ferritin, confirming the predominant effect of accelerated erythropoiesis on hepcidin production. Although the levels of a putative hepcidin suppressor, growth differentiation factor-15, were increased in PK-deficient patients, no negative correlation with hepcidin was found. This result indicates the existence of another as-yet unidentified erythroid regulator of hepcidin synthesis in PK deficiency.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica/genética , Ferritinas/sangre , Hepcidinas/sangre , Hierro/sangre , Mutación , Piruvato Quinasa/deficiencia , Piruvato Quinasa/genética , Errores Innatos del Metabolismo del Piruvato/genética , Adulto , Secuencia de Aminoácidos , Anemia Hemolítica Congénita no Esferocítica/sangre , Niño , Preescolar , Análisis Mutacional de ADN , Eritropoyesis , Femenino , Hepcidinas/biosíntesis , Humanos , Lactante , Recién Nacido , Sobrecarga de Hierro/genética , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Piruvato Quinasa/sangre , Errores Innatos del Metabolismo del Piruvato/sangre , Análisis de Secuencia de ADN , Reacción a la Transfusión , Adulto JovenRESUMEN
BACKGROUND: The group of unstable hemoglobins are associated with congenital non-spherocytic hemolytic anemia due to instability of the hemoglobin molecule. They often lead to formation of the characteristic inclusion bodies or Heinz bodies. AIM: To identity the cause of mild anemia, reticulocytosis, and hepatosplenomegly in a case of non-spherocytic hemolytic anemia. MATERIALS AND METHODS: A 34-year-old female patient originating from Maharashtra, western India presented with mild anemia and jaundice which had persisted since childhood. Investigations included a complete blood count, screening for red cell membrane protein defects, Hb analysis by high-performance liquid chromatography (HPLC) and cellulose acetate electrophoresis (pH 8.9), heat instability test and DNA sequencing. RESULTS: Hemoglobin analysis by HPLC showed an abnormal peak in the Hb C window (9.8%) with a retention time of 4.90 minutes. Cellulose acetate electrophoresis (pH 8.9) showed a slow moving band (6.15%) between Hb A2 and Hb S. The heat instability test was positive. DNA analysis of α globin genes showed absence of both deletional and non- deletional α thalassemia. DNA sequencing of the ß globin gene revealed heterozygosity for a mutation at codon 98 [GTG â ATG, Val â Met], which gives rise to Hb-Koln. CONCLUSION: Hb Koln is the commonest unstable Hb variant reported from many populations in the world. However, this is the first report of this unstable Hb variant from India.
Asunto(s)
Anemia Hemolítica Congénita no Esferocítica/genética , Hemoglobinas Anormales/genética , Globinas beta/genética , Adulto , Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica Congénita no Esferocítica/diagnóstico , Femenino , Heterocigoto , Humanos , India , Masculino , Linaje , Mutación Puntual , Análisis de Secuencia de ADNAsunto(s)
Anemia Hemolítica Congénita no Esferocítica/genética , Piruvato Quinasa/deficiencia , Errores Innatos del Metabolismo del Piruvato/genética , Rasgo Drepanocítico/genética , Adulto , Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica Congénita no Esferocítica/complicaciones , Niño , Índices de Eritrocitos , Femenino , Hemoglobina Falciforme/metabolismo , Heterocigoto , Humanos , Masculino , Mutación Missense , Oxígeno/sangre , Fenotipo , Mutación Puntual , Piruvato Quinasa/genética , Errores Innatos del Metabolismo del Piruvato/sangre , Errores Innatos del Metabolismo del Piruvato/enzimología , Rasgo Drepanocítico/sangre , Rasgo Drepanocítico/complicaciones , Globinas beta/genéticaRESUMEN
Malaria has occurred in the Cabo Verde archipelago with epidemic characteristics since its colonization. Nowadays, it occurs in Santiago Island alone and though prophylaxis is not recommended by the World Health Organization, studies have highlight the prospect of malaria becoming a serious public health problem as a result of the presence of antimalarial drug resistance associated with mutations in the parasite populations and underscore the need for tighter surveillance. Despite the presumptive weak immune status of the population, severe symptoms of malaria are not observed and many people present a subclinical course of the disease. No data on the prevalence of sickle-cell trait and red cell glucose-6-phosphate dehydrogenase deficiency (two classical genetic factors associated with resistance to severe malaria) were available for the Cabo Verde archipelago and, therefore, we studied the low morbidity from malaria in relation to the particular genetic characteristics of the human host population. We also included the analysis of the pyruvate kinase deficiency associated gene, reported as putatively associated with resistance to the disease. Allelic frequencies of the polymorphisms examined are closer to European than to African populations and no malaria selection signatures were found. No association was found between the analyzed human factors and infection but one result is of high interest: a linkage disequilibrium test revealed an association of distant loci in the PKLR gene and adjacent regions, only in non-infected individuals. This could mean a more conserved gene region selected in association to protection against the infection and/or the disease.
Asunto(s)
Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Malaria/genética , Adulto , Anemia Hemolítica Congénita no Esferocítica/sangre , Anemia Hemolítica Congénita no Esferocítica/genética , Cabo Verde , Eritrocitos/enzimología , Femenino , Frecuencia de los Genes , Glucosafosfato Deshidrogenasa/genética , Hemoglobina Falciforme/genética , Humanos , Isoenzimas/genética , Desequilibrio de Ligamiento , Hígado/enzimología , Malaria/sangre , Malaria/parasitología , Malaria/fisiopatología , Masculino , Plasmodium/parasitología , Polimorfismo Genético , Portugal , Piruvato Quinasa/genéticaRESUMEN
OBJECTIVE: Red cell adenylate kinase (AK) deficiency is a rare hereditary erythroenzymopathy associated with moderate to severe nonspherocytic hemolytic anemia and, in some cases, with mental retardation and psychomotor impairment. To date, diagnosis of AK deficiency depends upon demonstration of low enzyme activity in red blood cells and detection of mutations in AK1 gene. To investigate the molecular bases of the AK deficiency, we characterized five variants of AK1 isoenzyme-bearing mutations (118G>A, 190G>A, 382C>T, 418-420del, and 491A>G) found in AK-deficient patients with chronic hemolytic anemia. MATERIALS AND METHODS: The complete AK1 cDNA was obtained by standard procedures and using as template the reticulocyte RNA. The cDNA was cloned in a plasmid vector and the enzyme was expressed in Escherichia coli BL21(DE3)pLysS, and purified by standard protocols to homogeneity. DNA mutants bearing point mutations were obtained from the cloned wild-type cDNA using standard methods of site-directed mutagenesis, whereas the DNA mutant with deletion of codon 140 was obtained by a two-step method. RESULTS: Four mutant enzymes (Gly40Arg, Gly64Arg, Arg128Trp, Asp140del) were severely affected in activity, displaying a catalytic efficiency of four orders of magnitude lower than the wild-type; one (Tyr164Cys) was grossly perturbed in protein stability. CONCLUSIONS: The altered properties displayed by the mutant enzymes support the cause-effect relationship between AK1 mutations and hemolytic anemia.
Asunto(s)
Adenilato Quinasa/deficiencia , Adenilato Quinasa/genética , Anemia Hemolítica Congénita no Esferocítica/enzimología , Anemia Hemolítica Congénita no Esferocítica/genética , Eritrocitos/enzimología , Mutación , Adenosina Monofosfato/metabolismo , Adenosina Trifosfato/metabolismo , Adenilato Quinasa/sangre , Adenilato Quinasa/química , Anemia Hemolítica Congénita no Esferocítica/sangre , Dicroismo Circular , Estabilidad de Enzimas , Escherichia coli/genética , Mutación del Sistema de Lectura , Humanos , Cinética , Modelos Moleculares , Mutación Missense , Reacción en Cadena de la Polimerasa , Conformación Proteica , ARN/genética , ARN/aislamiento & purificación , Proteínas Recombinantes/sangre , Proteínas Recombinantes/química , Mapeo Restrictivo , Eliminación de SecuenciaRESUMEN
Red cell pyruvate kinase (PK) deficiency is the most frequent enzyme abnormality of the glycolytic pathway causing hereditary non-spherocytic haemolytic anaemia. The degree of haemolysis varies widely, ranging from very mild or fully compensated forms, to life-threatening neonatal anaemia and jaundice necessitating exchange transfusions. Erythrocyte PK is synthesized under the control of the PK-LR gene located on chromosome 1. To date, more than 150 different mutations in the PK-LR gene have been associated with PK deficiency. First attempts to delineate the biochemical and clinical consequences of the molecular defect were mainly based on the observation of the few homozygous patients and on the analysis of the three-dimensional structure of the enzyme. More recently, the comparison of the recombinant mutants of human red cell PK with the wild-type enzyme has enabled the effects of amino acid replacements on the enzyme molecular properties to be determined and help to correlate genotype to clinical phenotype.